- Stocks
- Healthcare
- NASDAQ: IART

Price (delayed)

$68.34

Market cap

$5.77B

P/E Ratio

43.25

Dividend/share

N/A

EPS

$1.58

Enterprise value

$6.95B

IART's EPS has surged by 168% year-on-year and by 136% since the previous quarter

Integra Lifesciences Holdings's net income has soared by 167% YoY and by 137% from the previous quarter

IART's quick ratio is down by 28% from the previous quarter but it is up by 21% YoY

The debt is up by 14% year-on-year

The gross profit has declined by 11% year-on-year

What are the main financial stats of IART

Market
Valuations
Earnings

Shares outstanding

84.37M

Market cap

$5.77B

Enterprise value

$6.95B

Price to earnings (P/E)

43.25

Price to book (P/B)

3.8

Price to sales (P/S)

4.22

EV/EBIT

42.1

EV/EBITDA

24.47

EV/Sales

5.07

Revenue

$1.37B

EBIT

$165.1M

EBITDA

$284.09M

Free cash flow

$168.6M

Per share
Balance sheet
Liquidity

EPS

$1.58

Free cash flow per share

$1.99

Book value per share

$17.98

Revenue per share

$16.21

TBVPS

$20

Total assets

$3.62B

Total liabilities

$2.1B

Debt

$1.66B

Equity

$1.51B

Working capital

$836.19M

Debt to equity

1.09

Current ratio

3.09

Quick ratio

1.73

Net debt/EBITDA

4.17

Margins
Efficiency
Dividend

EBITDA margin

20.7%

Gross margin

62%

Net margin

9.8%

Operating margin

11%

Return on assets

3.9%

Return on equity

9.6%

Return on invested capital

6.5%

Return on capital employed

5.1%

Return on sales

12%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Integra Lifesciences Holdings stock price performed over time

Intraday

-1.3%

1 week

0.18%

1 month

-2.18%

1 year

25.76%

YTD

5.27%

QTD

5.27%

How have Integra Lifesciences Holdings's revenue and profit performed over time

Revenue

$1.37B

Gross profit

$851.03M

Operating income

$151.37M

Net income

$133.89M

Gross margin

62%

Net margin

9.8%

The net margin has soared by 197% year-on-year and by 139% since the previous quarter

Integra Lifesciences Holdings's net income has soared by 167% YoY and by 137% from the previous quarter

IART's operating margin has soared by 77% year-on-year and by 12% since the previous quarter

The operating income has surged by 61% year-on-year and by 12% since the previous quarter

What is Integra Lifesciences Holdings's growth rate over time

What is Integra Lifesciences Holdings stock price valuation

P/E

43.25

P/B

3.8

P/S

4.22

EV/EBIT

42.1

EV/EBITDA

24.47

EV/Sales

5.07

IART's EPS has surged by 168% year-on-year and by 136% since the previous quarter

The stock's price to earnings (P/E) is 68% less than its 5-year quarterly average of 134.9

The P/B is 23% higher than the last 4 quarters average of 3.1 and 6% higher than the 5-year quarterly average of 3.6

The equity has increased by 8% since the previous quarter and by 7% year-on-year

The price to sales (P/S) is 36% more than the last 4 quarters average of 3.1 and 28% more than the 5-year quarterly average of 3.3

The revenue has declined by 10% year-on-year

How efficient is Integra Lifesciences Holdings business performance

Integra Lifesciences Holdings's return on equity has surged by 167% YoY and by 134% QoQ

IART's ROA has soared by 160% YoY and by 129% QoQ

IART's return on sales has surged by 60% year-on-year and by 11% since the previous quarter

IART's return on invested capital is up by 30% year-on-year and by 8% since the previous quarter

What is IART's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IART.

How did Integra Lifesciences Holdings financials performed over time

The company's total assets is 72% higher than its total liabilities

The current ratio has declined by 32% since the previous quarter but it has grown by 19% year-on-year

IART's quick ratio is down by 28% from the previous quarter but it is up by 21% YoY

The debt is 9% greater than the equity

The equity has increased by 8% since the previous quarter and by 7% year-on-year

Integra Lifesciences Holdings's debt to equity has decreased by 7% QoQ but it has increased by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.